Cross-Border Collaboration Facilitates Flagship Biotech Investments

Joint News Release
Date: November 5^th, 2023

Leading Taiwanese and Japanese biotech venture capitals ally. Diamond Biofund from Taiwan and DCI Partners Co., Ltd. (wholly owned by Daiwa Securities Group, referred to as DCI Partners) from Japan jointly announced that the two parties have established a cross-border investment collaboration to promote flagship biotech investment cases.

Diamond Biofund and DCI Partners are prominent biotech ventures. By this strategic alliances, they share their biotech investment resources in Taiwan and Japan, jointly develop investment projects with international market potential, and accelerate the in-depth collaboration in biotechnology, product, and market development to promote cross-border flagship investment deals.

Mr. William Lu, Chairman of Diamond Biofund, stated that Japan possesses global advantages in new drug development, cell therapy, and regenerative medicine. Taiwan, on the other hand, has established the worldclass capabilities in clinical medicine and technological innovation and provides a supportive capital market for the biotech sector. Both parties look forward to creating large-scale investment projects through IP licensing, equity investment or M&A, focusing on key areas with high market demand and commercial value in the future such as cell therapy, nucleic acid drugs, and regenerative medicine.

Mr. Hiroki Narita, CEO of DCI Partners, expressed that the strategy of the Daiwa’s biotech fund is to promote the collaboration between Taiwan and Japan. DCI Partners anticipate that the collaboration with Diamond Biofund will enhance the innovative capabilities in Taiwan and Japan, accelerating the creation of more cross-border investment opportunities and value.

---

About Diamond Biofund

Diamond Biofund Inc. (referred to as Diamond Biofund) is the first Taiwan Stock Exchange (TWSE)-listed evergreen biotech venture capital firm in Taiwan. With its mission to “Nurture Innovation for Better Quality of Life,” the firm specializes in biotechnology and medical investments. Diamond Biofund’s focus extends to globally competitive prospects, including new drug R&D, high-end medical equipment, innovative medical services and channels, and agricultural biotechnology. In addition to financial investment, Diamond Biofund provides invaluable support to portfolio companies in diverse areas, such as corporate governance, R&D, clinical implementation, business development, and capital market integration, all aimed at driving portfolio growth and delivering investment returns to shareholders.

---

About DCI Partners

DCI Partners Co., Ltd. (referred to as DCI Partners), a subsidiary of Daiwa Corporate Investment Co., Ltd. who is wholly owned by Daiwa Securities Group, is the venture investment arm specializing in the fields of biotechnology and healthcare. DCI Partners manages Japan’s largest biotechnology and medical fund, providing venture capital to startups poised to grow in the industry’s future. DCI Partners actively supports potential investments in biotechnology and pharmaceutical sectors in Taiwan and Japan, by leveraging its extensive network with research institutions, biotechnology companies, and pharmaceutical firms, as well as its specialized knowledge in drug development, intellectual property strategies, and licensing strategies, to promote the development of the biotechnology and pharmaceutical industries in both regions.

---

Press Contact:
Diamond Biofund
Patricia Chou
Patricia.chou@diamondbiofund.com

DCI Partners
Wei Fan Chen
weifan.chen@daiwa-inv.com.tw